SCHEMBL23613622

SCHEMBL23613622

CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)CF)[C@@H](C)O

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 11/20 0.56
CASP1 P29466 4/20 0.56
CASP9 P55211 4/20 0.56
CASP4 P49662 2/20 0.56
CASP5 P51878 2/20 0.56
CASP6 P55212 2/20 0.56
CASP8 Q14790 2/20 0.56
CASP10 Q92851 2/20 0.56
CASP7 P55210 2/20 0.54
CTSL P07711 2/20 0.50
CTSS P25774 2/20 0.50
CTSB P07858 2/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.49
CTSK P43235 1/20 0.47
REN P00797 1/20 0.46
PSMB5 P28074 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2040978 0.93 CASP3 (0.57) CASP3CASP1CASP9CASP4CASP5
SCHEMBL30541131 0.91 CASP3 (0.61) CASP3CASP1CASP9CASP4CASP5
SCHEMBL17814784 0.90 REN (0.52) CASP3CASP1CASP9CASP4CASP5
SCHEMBL28714127 0.90 REN (0.52) CASP3CASP1CASP9CASP4CASP5
SCHEMBL29449496 0.90 REN (0.52) CASP3CASP1CASP9CASP4CASP5
SCHEMBL20257276 0.90 CASP3 (0.60) CASP3CASP1CASP9CASP4CASP5
SCHEMBL2038060 0.88 CASP3 (0.63) CASP3CASP1CASP9CASP4CASP5
SCHEMBL31248472 0.87 CASP3 (0.63) CASP3CASP1CASP9CASP4CASP5
SCHEMBL23133285 0.84 CASP3 (0.57) CASP3CASP1CASP9CASP4CASP5
SCHEMBL21481085 0.84 CASP3 (0.57) CASP3CASP1CASP9CASP4CASP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3312273-B1 PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF UNIV TOKYO SCIENCE FOUND (JP) 2024-07-24 EP disclosed
US-11052154-B2 Ras protein degradation inducing molecule and pharmaceutical composition TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2021-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052154-B2 Ras protein degradation inducing molecule and pharmaceutical composition KRAS, G3BP1, NRAS CASP3 3966/4885CASP1 2718/4885CASP9 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.